Sequential Intravesical Gemcitabine and Docetaxel for bacillus Calmette-Guérin-Naïve High-Risk Nonmuscle-Invasive Bladder Cancer

Overview of attention for article published in The Journal of Urology, July 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (97th percentile)

Mentioned by

news: 30 news outlets
blogs: 3 blogs
twitter: 85 X users

reddit: 2 Redditors
guideline: 3 clinical guideline sources

Readers on

mendeley: 48 Mendeley

So far, Altmetric has seen 3 posts from 3 blogs.

For Common Form of Bladder Cancer, Chemo Combo Effective Alternative to BCG

Cancer Currents: An NCI Cancer Research Blog, 29 Aug 2022

The standard treatment for high-risk non-muscle-invasive bladder cancer (NMIBC), a drug called BCG, has been in shortage for a…

Gemcitabine/Docetaxel Treats Nonmuscle-Invasive Bladder Cancer

Physician's Weekly, 20 Aug 2022

FRIDAY, Aug. 19, 2022 (HealthDay News) — Gemcitabine plus docetaxel (Gem/Doce) may be an alternative for the treatment of high-ri…

Retrospective cohort study | Sequential Intravesical Gemcitabine and Docetaxel seem effective for high-risk BCG-naïve nonmuscle-invasive bladder cancer.

SPECIALTIES, 02 Aug 2022

Sequential Intravesical Gemcitabine and Docetaxel for bacillus Calmette-Guérin–Naïve High-Risk Nonmuscle-Invasive Bladder…

This page shows the most recent blog posts that mention this research output. Click here to find out how to access more activity.